Cited by

• Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic.

  Friedlaender A, Kim C, Addeo A. Friedlaender A, et al. Front Oncol. 2020 May 12;10:862. doi: 10.3389/fonc.2020.00862. eCollection 2020. Front Oncol. 2020. PMID: 32574277 Free PMC article.
• Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting.

  Durbin SM, Zubiri L, Niemierko A, Bardia A, Sullivan RJ, McEwen C, Mulvey TM, Allen IM, Lawrence DP, Cohen JV, Hochberg EP, Ryan DP, Petrillo LA, Reynolds KL. Durbin SM, et al. Oncologist. 2021 Jan;26(1):49-55. doi: 10.1002/onco.13561. Epub 2020 Nov 8. Oncologist. 2021. PMID: 33044765 Free PMC article.
• Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.

  Pons-Tostivint E, Hulo P, Guardiolle V, Bodot L, Rabeau A, Porte M, Hiret S, Demontrond P, Curcio H, Boudoussier A, Veillon R, Mayenga M, Dumenil C, Chatellier T, Gourraud PA, Mazieres J, Bennouna J. Pons-Tostivint E, et al. Cancer Immunol Immunother. 2023 Jun;72(6):1881-1890. doi: 10.1007/s00262-022-03359-2. Epub 2023 Jan 24. Cancer Immunol Immunother. 2023. PMID: 36690799 Free PMC article.
• SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.

  Mark M, Froesch P, Eboulet EI, Addeo A, Pless M, Rothschild SI, Janthur WD, Burmeister H, Friedlaender A, Schneider M, Metaxas Y, Joerger M, Wannesson L, Schwitter M, Baudoux N, Weindler S, Biaggi-Rudolf C, Früh M; Swiss Group for Clinical Cancer Research (SAKK). Mark M, et al. Cancer Immunol Immunother. 2021 May;70(5):1255-1262. doi: 10.1007/s00262-020-02757-8. Epub 2020 Nov 1. Cancer Immunol Immunother. 2021. PMID: 33130956 Free PMC article. Clinical Trial.
• Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status.

  Alessi JV, Ricciuti B, Jiménez-Aguilar E, Hong F, Wei Z, Nishino M, Plodkowski AJ, Sawan P, Luo J, Rizvi H, Carter BW, Heymach JV, Altan M, Hellmann M, Awad M. Alessi JV, et al. J Immunother Cancer. 2020 Aug;8(2):e001007. doi: 10.1136/jitc-2020-001007. J Immunother Cancer. 2020. PMID: 32753547 Free PMC article.